Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 12232
Sealed predictions
- STX12 in dopamine neurons, braak+0.83 (p 0.006) → +0.47 (p 0.197)receipt 12239
Swarm cases
receipt 12239: STX12 in dopamine neurons, braak
- power
- full sample +0.47 (p 0.049, n 18), 95% CI +0.01 to +0.77. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.48 (p 0.045, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.51 (p 0.032, n 18). not the mix.
- skeptic
- leave-one-out range +0.39 to +0.57, sign flips 0; without severely affected donors +0.47 (p 0.049, n 18). robust.
- cell type
- strongest in astrocytes: -0.75 (p 3.7e-4, n 18) vs +0.47 in dopamine neurons. proposing astrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for STX12 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up STX12 · astrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.57 p 0.041 (needs p < 1.8e-4)
Receipts
loading the receipts